백용한 (성균관대학교 의과대학, 삼성의료원)님 | 한빛사연구자 > 한빛사

성균관대학교 의과대학, 삼성의료원

최종업데이트

Hepatocellular carcinoma patients with high circulating cytotoxic T cells and intratumoral immune signature benefit from pembrolizumab: results from a single-arm phase 2 trial
- Genome Med., Published: 06 January 2022, 14, Article number: 1 | https://doi.org/10.1186/s13073-021-00995-8
- 2022-01
- 의약학
- 한빛사논문
Serum exosomal microRNAs as novel biomarkers for hepatocellular carcinoma
- Exp. Mol. Med., Published: 18 September 2015 | https://doi.org/10.1038/emm.2015.68
- 2015-09
- 의약학
- 상위피인용논문
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors
- J. Hepatol., 13 December 2014 | doi:10.1016/j.jhep.2014.12.009
- 2014-12
- 의약학
- 한빛사논문
Patients with chronic hepatitis B treated with oral antiviral therapy retain a higher risk for HCC compared with patients with inactive stage disease
- Gut, doi:10.1136/gutjnl-2013-306409
- 2014-03
- 한빛사논문

연구자 ID

저자논문